Member Info for TrickyEFC

Less than £2k bought and they moving it up

Hopefully he finishes and they still offering pieces of8 😜and not7s

£5k seller trying to let water onto the boat

Looking good for early movement

Makes me chuckle that he previously provided rapid growth to the Alcohol industry, playing the LONG game I see 😂

George has 15 years experience leading companies in highly regulated industries to rapid growth, including alcohol, energy drinks and, most recently, medical cannabis.

Formerly President of Red Bull Canada, he was instrumental in restructuring the organisation and growing the business to $150 MM in revenue

Big Hitter indeed. Hope he sees a hit here.

including $33 billion of revenue in 2015 and launching several of the biggest selling prescription drugs of all time

("Solvonis" or the "Company")

Strengthens Board with Appointment of Pharmaceutical Industry Executive Dr. Renata Crome as Non-Executive Director

Solvonis Therapeutics plc (LSE:SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to announce the appointment of pharmaceutical industry veteran, Dr. Renata Crome DSc, MBA, MFPM, as an independent Non-Executive Director, effective from 11 March 2025.

Dr. Crome brings over 40 years of experience in scientific and clinical development, regulatory approval, and commercialisation of breakthrough medicines. A recognised leader in CNS (Central Nervous System), oncology, and infectious diseases, Dr. Crome has guided more than 100 novel therapies from early-stage research to first-in-human clinical trials.

During her 30-year tenure at Roche, Dr. Crome progressed through increasingly senior roles, ultimately becoming Deputy Head of Early Development & Global Head of Development Operations. In this capacity, she led a team of over 250 professionals and managed a portfolio of more than 100 early development programmes across several therapeutic areas, including CNS, a key area of focus for Solvonis.

Dr. Crome's strategic leadership has been pivotal in the commercialisation of several blockbuster drugs, including leading the prioritisation of Avastin® and Tamiflu®, resulting in rapid regulatory approvals and the realisation of US$7 billion and US$3 billion peak annual sales respectively for Roche. These achievements reflect her ability to drive the development of impactful treatments

Solvonis Chairman Dennis Purcell is Founder and Senior Advisor at Aisling Capital. During his tenure, Dennis has been directly involved with over two hundred completed transactions and supervised over $15 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist). Dennis is a frequent commentator on the industry and has been honored in various publications as a top contributor to the Life Sciences Industry. He sits on numerous private and public healthcare company boards, such as Real Endpoints and Summus Global. He is actively involved with many of the industry’s professional organizations. He is Executive Chairman of Poliwogg Holdings, a company devising new financed products for the healthcare industry. Dennis received his M.B.A. from Harvard University and his B.S. in Accounting from the University of Delaware

Fantastic experience and more importantly very well connected to the big players.

Ps looks like Chuck from Better Call Saul.

Paul Carter is a seasoned international BioPharma leader with an outstanding and proven track record. He has over 25 years of senior executive experience, specializing in commercialization, regional leadership and mergers and acquisitions. Mr. Carter is currently a Board Director and Committee Chair of four US listed BioPharma companies HutchMed PLC, Mallinckrodt Pharmaceuticals, Immatics NV, and VectivBio Inc.

Prior to this, Mr. Carter served as Executive Vice-President and Chief Commercial Officer of Gilead Sciences Inc., where he was responsible for the company’s worldwide commercial activity, including $33 billion of revenue in 2015 and launching several of the biggest selling prescription drugs of all time. Before that Paul had senior leadership roles in GSK (and its legacy companies), including head of GSK China and head of Smith Kline Beecham Russia. He has lived and worked extensively in the US, Europe and Asia and continues to be strongly networked and professionally connected to a diverse range of publicly listed and private life science orientated businesses in these territories.

Which would require about two 15/20% days.

Given that less than £40k shifted it 14% on Friday it's doable alreet.

hopefully this week will confirm the new bottom is in the mid 0.20s never to see sub 0.20s again.

Hoping for a Wednesday RNs with the price ready already at 0.23p by close on Tuesday ready to finally clear 24 🐎🐎

Giddy up

If they can execute the AUD to commercial stage.

Then what's next.

Awakn is developing a Medication-Assisted Treatments for Alcohol Use Disorder with potential to expand into other addiction in time.

Awakn’s MATs target the brain circuits that drive addiction. These circuits control the behavioural drivers of addiction.

This disruption allows the individual to escape from the repetitive addictive behaviours and thoughts, and in doing so engage with a psychotherapeutic process to enable lasting positive change.

Our therapies work in conjunction with our medicines enabling the patients to regain control over their lives and helping them to learn new more adaptive ways to respond to addictive urges, cravings and the underlying processes that drive them.

Our therapies are manualized and our protocols are condensed to ensure efficient use of healthcare resources, including people, time, and real estate.

Musk your situational awareness (after the fact also ) is shocking.

Blind you are

Elight musk

No but signal. Are you mental????

On Tuesday you could buy for 0.72.

You can now sell for 0.84.

Fool

We may need a bigger boat 💲💲💲💲

Edit

Sorry it would give us a market cap of £22.8 million with a cash balance of £13.2mill

Based on 9.5bill shares at 0.24p.

Fair rerate value of 0.45 (£42mcap) to 0.55p (£52mill) as we move on down the road.

Afternoon bones. Cheers. Obviously I am like everyone else and have no real idea what raise will be at but looking at all the angles it looks as if it may turn out to be pretty tasty. However even if they got stitched at 0.12p It would not be bad as we only need runway till next year by then we will have a much clearer indication if awkn01 is gonna be a commercial hit. If they raise at 0.24p I'd honestly expect a nice chunk of cash in the companies account getting interest. If they got the full amount issued at 0.24p that would give them a cash balance of over double the current market cap of the enlarged group.

What's that phrase. The only way is up!

If they can raise at 0.24p just 2bill shares would give us £4.8 mill in cash and leave over 2bill shares to call on if needed.

I would not complain about that at all.

Have a good weekend all and next week should be proper hot here

Samsmith will the fundraise be above 0.24p?

Not long to wait